Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HeXell-2020 in Patients With Stable Coronary Artery Disease (CAD)
NCT07137104Phase 2Recruiting
- Sponsor
- HeXun Biosciences
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of HeXell-2020 in coronary artery disease (CAD), sponsored by HeXun Biosciences. Started Aug 2026; status: recruiting.
02
Drugs
HeXell-2020
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT07137104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07137104.